Diğer Kripto Paralara Git
ABRIDGEAbridge
Abridge
ABRIDGECan retail traders trade Abridge? Abridge is not listed on any stock exchange, and its private secondary markets are mostly restricted to accredited investors. CoinUnited offers a synthetic CFD reference — price exposure only, not equity (no voting, dividends, or IPO allocation) — tradable by eligible users from US$100, with no accreditation. Access terms vary by jurisdiction and product eligibility.
Company snapshot
Temel bilgiler
Bu şirket hakkında en çok alıntılanan veriler, her biri kaynağıyla birlikte: okuyucular ve yapay zekâ yanıt motorları için hızlı başvuru kutusu.
Birincil kaynak: Notice (private-market data)
| Sektör | Healthcare |
|---|---|
| Çalışan sayısı | 677 |
| Son açıklanan değerleme | $6B (as of 2026-10-09) |
| Son yatırım turu | $5.3B (Series E) |
| Halka açıklık durumu | Halka açık değil; doğrulanmış halka arz başvurusu yokCoinUnited (as of generation) |
| CoinUnited ürünü | Sentetik CFD referans fiyatı - hisse mülkiyeti değildir (oy hakkı, temettü veya halka arz tahsisi yoktur); 100 US$'dan itibaren işlem yapılabilir.CoinUnited ürün koşulları |
Cross-Venue Reference Price
CoinUnited’s reference price shown side by side with named private secondary-market venues — one glance shows where CoinUnited sits and the spread across venues.
Each venue uses a different pricing methodology (last-trade, model-derived estimate, synthetic CFD reference), so figures are indicative and not directly comparable. The dispersion between venues is itself information — more honest than a single price.
CoinUnited’s pre-IPO reference price blends several observable inputs — recent private-secondary transaction marks, the latest primary funding-round valuation, and public-market comparables — weighted toward the most recent and most corroborated data. Because pre-IPO shares change hands infrequently and off-exchange, no single “true” price exists: the quoted spread reflects this genuine uncertainty rather than a fixed markup, widening when venue dispersion or data staleness rises and tightening as fresh, corroborated marks arrive. This keeps the reference honest to how thinly the underlying actually trades.
Machine-readable table — same numbers, per-venue source
| Venue | Reference | As of | Source |
|---|---|---|---|
| Forge Global | $200.00 | 2026-10-23 | forgeglobal.com |
| Notice | $182.81 | 2026-10-23 | notice.co |
| Nasdaq Private Market | $180.70 | 2026-10-23 | nasdaqprivatemarket.com |
| Hiive | $174.71 | 2026-10-23 | hiive.com |
Indicative reference prices, not executable quotes. The CoinUnited figure is a synthetic CFD reference (not equity; no voting, dividend, or IPO allocation). CoinUnited does not provide price targets or guarantee returns.
Valuation & financials
Pre-IPO Peer Valuations
How this company's current valuation compares to nearby pre-IPO names we cover — structured private-market marks, not a public EV/Sales multiple.
Machine-readable table — same peers, valuation + source
| Company | Valuation | Source |
|---|---|---|
| Plaid | $6.1B | Notice |
| Hark AI | $6B | Notice |
| Suno | $5.94B | Notice |
| Abridge | $5.88B | Notice |
| Flock Safety | $5.24B | Notice |
| PsiQuantum | $4.78B | Notice |
| Notion | $4.71B | Notice |
Notice.co secondary-market marks, as of {d}. Private valuations move with each trade.
How you trade it
Access & Tradability Comparison
The same company across different venues — access terms and eligibility. A direct answer to the highest-intent question: how can a retail investor actually get exposure?
| Terms | CoinUnited | Nasdaq Private Market | Hiive | Forge / EquityZen |
|---|---|---|---|---|
| Product type | Synthetic CFD | Private secondary equity | Private secondary equity | Private secondary equity |
| Is it equity? | No (price exposure) | Yes | Yes | Yes |
| Accredited investor required | No* | Yes | Yes | Yes |
| Minimum ticket | Low* | High | High | High |
| Shareholder rights | None (no voting / dividend / IPO allocation) | Yes | Yes | Yes |
*Access and minimum vary by jurisdiction and product eligibility.
How the ABRIDGE CFD works
Before you trade, understand exactly what you get, what you don't, and where the risk sits.
Price exposure to the ABRIDGE reference (a synthetic CFD) that tracks the CoinUnited reference up and down.
It is not equity: no shares, no voting rights, no dividends, no IPO allocation.
The CoinUnited reference may carry a spread or premium versus secondary-market prices; the two need not move in lockstep.
Fiyat & Piyasa Yapısı
Ticaret Rejimi Durumu
Understand the risks
Trading Risks
An honest, up-front list of the risks — both out of respect for the trader and as a YMYL compliance requirement.
High leverage means a small adverse move can trigger forced liquidation and loss of your full margin.
The reference price can diverge from any single secondary-market execution price.
Pre-IPO secondary markets are thin and price slowly; the reference updates on a limited cadence.
The company faces cross-border regulatory and geopolitical uncertainty.
Private valuations lack audited public financials; ranges can swing materially.
No formal IPO filing; timing and final pricing are highly uncertain.
Deep dive
What Is Abridge?
TL;DR
Abridge is a private AI company that automates clinical documentation for healthcare providers; retail traders can access synthetic price exposure to its private-market valuation via a pre-IPO CFD on CoinUnited from US$100, with no accreditation required.
Abridge is a US-based private company that develops AI-powered ambient clinical documentation software, designed to reduce the administrative workload carried by physicians and clinicians. The company is not publicly listed on any stock exchange. Retail price exposure is available through CoinUnited's pre-IPO CFD instrument from US$100, with no accreditation requirement.
That instrument is a synthetic contract for difference (CFD): it tracks a private-market reference price for Abridge and confers no shareholding, voting rights, dividends, or allocation in any future IPO.
Core Product and Business Model
Abridge's principal product listens passively to physician-patient conversations and automatically generates structured clinical notes, discharge summaries, and referral letters. The output integrates with major electronic health record (EHR) platforms, allowing clinicians to review and sign documentation without manually transcribing visit details.
The target customers are hospitals, health systems, and individual clinicians for whom administrative burden, often described in the industry as a leading driver of physician burnout, represents a measurable operational cost.
The business model centres on licensing agreements with health systems, which pay for access at the enterprise level. This creates a recurring-revenue profile, with deployment scale driven by the number of clinicians using the tool within a contracted institution.
Competitive Landscape
Abridge competes in a sector that has attracted significant capital and large incumbents. Microsoft's Nuance DAX product, Google's healthcare AI initiatives, and a cohort of well-funded startups all target the same clinical documentation workflow.
Abridge's positioning within this field rests on reported partnerships with prominent health systems, which provide both revenue and credibility as reference accounts for further enterprise sales.
The competitive intensity of the ambient documentation category means that partnership announcements, EHR integration depth, and clinical accuracy benchmarks are the primary differentiators investors and health system procurement teams evaluate.
Private Valuation and Investor Interest
Abridge has raised successive funding rounds, and its private valuation has trended upward across those rounds, reflecting sustained demand from health systems for workflow automation and broader investor appetite for healthcare AI as a category. As of October 2026, the company remains private, and its financials are not publicly disclosed.
The 2026 Pre-IPO Market Outlook provides wider context on how private healthcare technology names have been valued and traded in the secondary market this year.
Accessing Abridge Price Exposure on CoinUnited
Because Abridge is private, conventional brokerage accounts cannot offer exposure to its price movements. CoinUnited's pre-IPO CFD fills that gap synthetically. The instrument follows a scheduled trading session and is closed at weekends and on market holidays; the session schedule and applicable holiday calendar are shown on the platform before any trade is placed.
Accounts are funded and withdrawn in crypto, removing the need for a traditional bank account or the paperwork associated with conventional brokerages. Trading fees apply and are not zero at the standard tier; they are tiered across nine VIP levels by 30-day contract volume, with the full schedule published at coinunited.io/en/account/trading-fees.
Eligibility and availability are subject to applicable product and jurisdictional conditions.
Son güncelleme: 2026-10-10
Anahtar Gözlemler
- Abridge operates in AI-assisted clinical documentation, a sector attracting sustained interest from large health systems and strategic investors as hospitals face persistent physician burnout and administrative overload.
- As a private company, Abridge has no public financials; its valuation is determined by successive funding rounds and secondary-market indications, meaning price discovery is thinner and more episodic than for listed equities.
- The primary access barrier for most retail participants is accreditation: traditional pre-IPO platforms such as EquityZen, Forge Global, and Hiive typically require investors to meet high financial thresholds, whereas CoinUnited's pre-IPO CFD offers synthetic price exposure from US$100 with no accreditation requirement.
- Healthcare AI is subject to layered regulatory scrutiny, FDA oversight of software-as-a-medical-device, HIPAA compliance, and hospital procurement cycles, which can extend commercialization timelines and introduce valuation uncertainty not present in consumer tech pre-IPO names.
- A pre-IPO CFD on Abridge is a leveraged synthetic instrument that tracks the private-market reference price; it confers no shareholding, voting rights, dividends, or IPO allocation, and losses can exceed expectations if leverage is applied without disciplined position sizing.
Why Trade the Abridge Pre-IPO CFD?
The case for gaining synthetic price exposure to Abridge through a CFD rests on three distinct considerations: the structural access problem that most retail traders face with private-market names, the qualitative growth narrative underpinning Abridge's valuation trajectory, and a set of material risks that are specific to pre-IPO instruments in regulated AI sectors.
Each deserves careful examination before committing capital.
The Access Wedge
Traditional pre-IPO investment channels, secondary marketplaces, private placement funds, and direct participation in funding rounds, are typically restricted to accredited investors. That qualification, in the US context, generally requires either a sustained income above defined thresholds or a net worth well in excess of US$1 million, excluding primary residence.
Minimum ticket sizes on institutional secondary platforms frequently begin at US$10,000 or higher, and the due-diligence process often involves both paperwork and extended timelines.
CoinUnited's pre-IPO CFD on Abridge provides synthetic price exposure from US$100, with no accreditation requirement. Accounts are funded via crypto, so no traditional bank account is needed and onboarding avoids the documentation burden of conventional brokerages.
The instrument is a contract for difference that tracks a private-market reference price: it is not equity, confers no shareholding, voting rights, or dividends, and carries no entitlement to any future IPO allocation. What it provides is price exposure, a way to express a view on Abridge's private valuation without meeting the financial qualification bar that would otherwise apply.
The session follows a scheduled calendar; the trading hours and holiday schedule are shown on the platform before any order is placed.
The Structural Growth Case
Abridge's valuation has re-rated upward across successive funding rounds, and the underlying demand drivers are well-documented. Physician burnout linked to administrative documentation is a recognised operational problem for health systems.
EHR compliance requirements impose substantial time costs on clinicians, surveys across the medical industry consistently show that documentation consumes a large fraction of a physician's working day.
Ambient AI tools that automatically generate structured clinical notes address this cost directly, and large language model capabilities have improved to the point where health systems are deploying such tools at an accelerating pace.
Abridge has secured named partnerships with major academic medical centres, which function as high-credibility reference accounts in enterprise procurement cycles. Each partnership both generates recurring licensing revenue and validates the product for the next prospective health system buyer.
Private-market secondary indications have generally tracked above prior primary round prices, reflecting the premium that strategic and financial investors have been willing to assign to defensible AI-in-healthcare positions with demonstrable health system adoption.
Pre-IPO-Specific Risk Factors
The risks attached to this instrument are qualitatively different from those of a listed equity and warrant explicit acknowledgement.
| Risk Category | Description |
|---|---|
| IPO delay or cancellation | No confirmed IPO timeline exists as of late 2026. The company may remain private indefinitely, delaying or eliminating any liquidity event. |
| Regulatory risk | FDA and CMS oversight of AI in clinical settings is evolving. Adverse rulings could constrain the product's commercial scope or require costly modifications. |
| HIPAA compliance | Clinical data handling imposes stringent compliance obligations; any breach or enforcement action carries reputational and financial consequences. |
| Concentration risk | Revenue concentration in a limited number of health system contracts means non-renewal by a key partner would be materially adverse. |
| Valuation uncertainty | Private-market prices are estimates, not exchange-discovered prices; bid-ask spreads and reference price changes can be wide and abrupt. |
Beyond these company-specific factors, the CFD structure itself introduces instrument-level risk. Leverage amplifies both gains and losses relative to the margin posted. A position can be liquidated if adverse price moves erode account equity below margin thresholds, partial recovery of principal is not guaranteed, and losses can equal or exceed the margin deposited.
The maximum leverage available on this instrument is 100x, subject to product, jurisdiction, and account eligibility; its use materially increases the speed and magnitude of potential loss.
Trading fees apply and are not zero at the standard tier; the fee schedule, which is tiered by 30-day contract volume, is published at coinunited.io/en/account/trading-fees.
Traders weighing this instrument should assess these risk factors against their own exposure limits and not treat the CFD as a substitute for equity ownership in Abridge or as a guaranteed path to participating in any eventual IPO upside.
Trading conditions on CoinUnited
Fee schedule as of 2026-08-19| Product type | CFD | Synthetic price exposure. You do not hold the underlying asset. |
|---|---|---|
| Trading fee | 0,070% | Per side, at the standard tier. Falls with 30-day volume and reaches 0.000% at VIP 9. |
| Trading hours | Market session | Follows the market session and is closed at weekends and on market holidays. |
| Kaldıraç - gün içi | 100x | Aktif işlem saatleri içinde geçerlidir. En küçük pozisyon büyüklüğünde 0,500% teminat gerektirir. Kullanılabilirlik ve üst sınır; ürüne, yetki alanına ve hesap uygunluğuna göre değişir; kaldıraç zararları büyütür ve pozisyonlar likide edilebilir. |
| Kaldıraç - gecelik | 10x | İşlem günü sonrasına taşınan pozisyonlar için geçerlidir. En küçük pozisyon büyüklüğünde 5,000% teminat gerektirir. |
| Kaldıraç - hafta sonu ve tatiller | 10x | Piyasa kapalıyken taşınan pozisyonlar için geçerlidir. En küçük pozisyon büyüklüğünde 5,000% teminat gerektirir - pozisyonunuzu hafta sonuna taşımadan önce büyüklüğünü kontrol edin. |
| Direction | Long or short | Take a position in either direction. A short position profits when the price falls and loses when it rises. |
| Funding | Crypto deposit | Fund and withdraw in crypto. No bank transfer or card is required. |
Trading Abridge on CoinUnited.io: Mechanics, Sizing, and Pre-IPO Considerations
The CoinUnited Abridge instrument is a synthetic CFD that gives price exposure to Abridge's private-market reference price. It is not equity, not a forward purchase of shares, and not an IPO allocation. Understanding how the instrument is constructed, how leverage behaves within it, and where its specific risks concentrate is the foundation for using it deliberately.
How the Synthetic CFD Works
Because Abridge is private, no public exchange quote exists. The reference price tracked by the CoinUnited CFD is derived from secondary-market indications and funding-round data, the same information sources institutional participants use when pricing private-company exposure. This has practical consequences for traders.
First, the reference price does not update continuously in the way a liquid public stock does. It can gap, moving sharply between sessions, when material information emerges: a new funding round, a significant health system partnership, a leadership change, or a broad risk-off move in private-market valuations.
Second, spreads on this instrument may widen during low-liquidity periods, particularly around major news events or at the edges of the trading session. Both factors are normal for a pre-IPO instrument and should be factored into position sizing before entry.
Leverage Specification and Liquidation Mechanics
The maximum leverage available on the CoinUnited Abridge pre-IPO CFD is 100x, subject to product eligibility and jurisdiction. This figure is a product specification. It amplifies losses by the same factor it amplifies gains, and at maximum leverage the margin for error is extremely narrow.
At 100x, a US$100 margin controls US$10,000 in notional exposure. A 1% adverse move in the reference price produces a US$100 loss, equal to the entire margin, and can trigger liquidation. The relationship is linear and unforgiving: there is no buffer once the reference price moves against a fully leveraged position by the percentage equivalent to the inverse of the leverage multiple.
Trading fees apply to this market. Fees are tiered by 30-day contract volume across nine VIP levels and reach 0.000% only at VIP 9, which requires 30-day volume of 20,000,000,000 USDT or a balance of 200,000,000 USDT. The live fee rate for a given account tier is shown on the CoinUnited fee schedule.
Worked Example: Position Sizing at 100x
The following is a hypothetical illustration of how the arithmetic operates at maximum leverage.
| Parameter | Value |
|---|---|
| Margin posted | US$200 |
| Leverage applied | 100x |
| Notional exposure | US$20,000 |
| Reference price move (scenario A) | +2% |
| Gain (scenario A) | US$400, 200% return on margin |
| Reference price move (scenario B) | −2% |
| Loss (scenario B) | US$400, exceeds margin, triggers liquidation |
Step by step for scenario B: US$20,000 notional × 2% adverse move = US$400 loss. The posted margin is US$200. The loss exceeds the margin before the reference price has moved 2%, so the position is liquidated before the full 2% move completes.
This illustrates that at 100x leverage, the distance between entry and liquidation is approximately 1%, and for a pre-IPO instrument where the reference price can gap overnight, that distance can be crossed without any opportunity to react.
Position size relative to total account equity is the primary risk control available to a trader. Reducing leverage, or posting margin that represents a small fraction of account equity, preserves the ability to remain in a position through normal reference-price volatility.
Weekend Gap Risk
The Abridge instrument follows a scheduled trading session and is closed at weekends and on market holidays. The session calendar and any applicable holidays are shown on the platform before trading.
Private-company valuation events, funding announcements, partnership deals, adverse regulatory rulings, or changes in broader healthcare AI sentiment, are not constrained to market hours. They occur continuously, including while the CoinUnited market is closed. When the market reopens, the reference price may reflect a materially different level from the prior close.
Traders holding positions into a session close carry this gap exposure with no ability to exit or adjust until the market reopens. This is a specific and measurable risk in pre-IPO instruments that does not diminish with leverage reduction alone, it requires a deliberate decision about whether to hold through the close at all.
IPO Event Handling and Practical Considerations
If Abridge completes an IPO while a CFD position is open, CoinUnited's platform terms govern how the synthetic position is settled or transitioned. Traders intending to hold exposure through a potential IPO window should review the platform's event-handling policy before doing so.
The mechanics of settlement in that scenario are distinct from normal position management and are not equivalent to receiving IPO shares.
Entry and exit liquidity in pre-IPO CFDs is narrower than in large-cap public equities. Limit orders, rather than market orders, give a trader more control over execution price during periods when spreads may widen.
Awareness of the session calendar, when the market opens, when it closes, and when holidays apply, is a practical tool for avoiding unintended gap exposure rather than an administrative detail.
Sıkça Sorulan Sorular
Abridge is not publicly listed on any stock exchange. It remains a private company, meaning its shares are not available through conventional equity markets such as the NYSE or NASDAQ. Access to its equity is generally restricted to institutional investors, venture capital firms, and other private-market participants under standard arrangements. Because Abridge has not completed an IPO, there is no public ticker or exchange-listed share price. The CoinUnited instrument tracks a private-market reference price for Abridge, offering synthetic price exposure through a CFD structure rather than through any publicly traded security. This distinction matters: the reference price reflects private-market valuation dynamics, which can differ substantially from how a post-IPO public market might price the same company.
Sözlük
Halka arz öncesi ve CFD'lerin temel terimleri, her biri tek satırda: sayfanın hem okuyucular hem de yapay zekâ yanıt motorları için belirsizlikten uzak olması için.
| Halka arz öncesi | Bir şirketin halka açılmasından önceki aşama; ilgili değerlemeler yatırım turlarından, geri alımlardan, pay alım tekliflerinden veya özel ikincil işlemlerden gelir. |
|---|---|
| Sentetik CFD | Yalnızca fiyat maruziyeti sağlayan bir fark sözleşmesi: ilgili şirketin hisselerinin mülkiyetini temsil etmez. |
| İkincil piyasa | Özel şirket hissedarlarının nitelikli yatırımcılarla işlem yaptığı piyasa; likidite ve devir kısıtları nedeniyle fiyatlar birbirinden ayrışabilir. |
| Nitelikli yatırımcı | Belirli varlık, gelir veya mesleki eşikleri karşılayan yatırımcı; özel ikincil platformların çoğu yalnızca bu kullanıcılara hizmet verir. |
| Referans fiyat | Fiyatlama veya bilgi gösterimi için kullanılan gösterge niteliğinde bir değer; mutlaka işlem yapılabilir bir kotasyon değildir. |
| Baz riski | CFD referans fiyatı ile ikincil piyasadaki hisse fiyatının (veya nihai halka arz fiyatının) aynı yönde hareket etmeme riski. |
| GMV | Brüt Mal Hacmi — bir platformdaki toplam işlem değeri; ticaretin ölçeğini yansıtır, geliri veya kârı değil. |
| İma edilen değerleme | Bir hisse veya işlem fiyatı ile hisse sayısından çıkarılan şirket değeri; özel şirketler için kaynak ve tarih taşıması zorunludur. |
sembol
ABRIDGE
Pazarlar
Pre-IPO
CU Ürün Kodu
ABRIDGE
Sources & References
Feragatnameler & Referanslar
Önemli Risk Uyarısı
Pre-IPO CFD reference prices for Abridge are indicative only: they may be illiquid, discrete, stale, or differ from any future IPO price, and are not official equity valuations or executable quotes.
A CFD provides price exposure only, not equity ownership: no voting rights, no dividends, no IPO allocation.
Kullanıcıların, herhangi bir yatırım kararı almadan önce kendi araştırmalarını yapmaları ve nitelikli finans profesyonellerine danışmaları önerilir. Bu platformun oluşturucuları ve işletmecileri, sağlanan bilgilere dayanarak oluşabilecek herhangi bir finansal kayıp veya diğer zararlar için hiçbir sorumluluk kabul etmezler.
cu.disclaimer_risk_investment
Metodoloji Genel Bakış
Private-market reference methodology uses secondary-market indications, reported private transactions, tender-offer marks, funding-round valuation marks, comparable-company multiples, and venue quotes with source freshness. Reference prices may be stale, discrete, indicative, or unavailable, and should not be treated as official equity valuation or executable quotes.
Son metodoloji gözden geçirmesi:

ABRIDGE
Abridge
Live from CoinUnited.io